Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Chengdu Okay Pharmaceutical Co Days Payable?
Chengdu Okay Pharmaceutical CoBJSE:920230 73 Days Payable is 62.45 as of Jun. 2026, which is 14% above its 10-year median of 54.98. GuruFocus rates BJSE:920230 with a GF Score™ of 73/100 and a GF Value™ of ¥11.12 (Fairly Valued). The stock has 7 warning signs investors should review. Among 925 Drug Manufacturers companies, Chengdu Okay Pharmaceutical Co ranks worse than 66.05% on this metric.
The historical rank and industry rank for Chengdu Okay Pharmaceutical Co's Days Payable or its related term are showing as below:
BJSE:920230'
s Days Payable Range Over the Past 10 Years
Min: 22.02 Med: 54.98 Max: 99.74
Current: 61.04
During the past 13 years, Chengdu Okay Pharmaceutical Co's highest Days Payable was 99.74. The lowest was 22.02. And the median was 54.98.
BJSE:920230's Days Payable is ranked worse than 66.05% of 925
companies
in the Drug Manufacturers industry
Industry Median: 88.64
vs BJSE:920230: 61.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Chengdu Okay Pharmaceutical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengdu Okay Pharmaceutical Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chengdu Okay Pharmaceutical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Chengdu Okay Pharmaceutical Co's Days Payable falls into.
Chengdu Okay Pharmaceutical Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Okay Pharmaceutical Co (BJSE:920230) has a Days Payable of 62.45 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Chengdu Okay Pharmaceutical Co and its competitors. This is 14% above median its historical median of 54.98. Over the past decade, Chengdu Okay Pharmaceutical Co's Days Payable has ranged from 22.02 to 99.74. According to the industry distribution chart, Chengdu Okay Pharmaceutical Co ranks #611 out of 925 companies in the Drug Manufacturers industry, placing it in the top 66.1%.
Is Chengdu Okay Pharmaceutical Co's Days Payable too high?
Chengdu Okay Pharmaceutical Co's current Days Payable of 62.45 is 14% above median its 10-year median of 54.98. Over the past 10 years, this metric has ranged from a low of 22.02 to a high of 99.74. The Drug Manufacturers industry median Days Payable is 88.64. Chengdu Okay Pharmaceutical Co's value of 62.45 is 29.5% below this industry median. Based on the distribution chart, Chengdu Okay Pharmaceutical Co ranks #611 out of 925 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Chengdu Okay Pharmaceutical Co has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Okay Pharmaceutical Co's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Chengdu Okay Pharmaceutical Co ranks #611 out of 925 companies for Days Payable. This places Chengdu Okay Pharmaceutical Co in the lower half of its industry. The industry median Days Payable is 88.64. Chengdu Okay Pharmaceutical Co's value of 62.45 is 29.5% below this benchmark. Historically, Chengdu Okay Pharmaceutical Co's own Days Payable has ranged from 22.02 to 99.74 over the past decade. While the company's 10-year median is 54.98 vs. the industry median of 88.64, Chengdu Okay Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.64, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chengdu Okay Pharmaceutical Co's current Days Payable of 62.45 is 29.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Chengdu Okay Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chengdu Okay Pharmaceutical Co's current Days Payable is 62.45, which is 14% above median its own 10-year median of 54.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Okay Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Okay Pharmaceutical Co (BJSE:920230) is currently considered Fairly Valued. The stock's GF Value™ is ¥11.12, compared to a current price of ¥11.64 — trading 4.7% above its estimated fair value. The current Days Payable is 62.45, which is 14% above median its 10-year median of 54.98 and 29.5% below the Drug Manufacturers industry median of 88.64. Chengdu Okay Pharmaceutical Co's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Chengdu Okay Pharmaceutical Co (BJSE:920230), the current Days Payable is 62.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Okay Pharmaceutical Co (BJSE:920230) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Okay Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥11.64 is trading 4.7% above its estimated GF Value™ of ¥11.12.
GuruFocus considers Chengdu Okay Pharmaceutical Co to be Fairly Valued.
Key valuation signals for BJSE:920230:
Days Payable: 62.45 (14% above median its 10-year median of 54.98)
GF Value™: ¥11.12 vs. price of ¥11.64 (4.7% above fair value)
Industry Position: 29.5% below the Drug Manufacturers median (#611 of 925)
No single metric tells the full story. See the BJSE:920230 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Okay Pharmaceutical Co Ltd engages in research and development, production, and sales of plant extracts. It specializes in natural vitamin P products, including large-scale professional planting, extraction, purification, synthesis, and application. Its product series include Citrus Extract Series, Sophorae Japonica Series, and Miscellaneous Extract Series.
73GF Score
Get the complete analysis for BJSE:920230
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920230 has been successfully added to your 
